Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients.

Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment #United_States #Florida_Cancer_Specialists #Fort_Myers #KRAS_G12D #setidegrasib

MSK gastrointestinal medical oncologist Dr. Wungki Park led a global phase 1 clinical trial of #setidegrasib, which shows early promise in aggressive #lung and #pancreatic cancers.

Learn more about this research: https://bit.ly/3Nsijjm